Clinical Trial

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-17.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-04-11
Trial Details
NCT Number NCT05864014
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Chemotherapy-Induced Thrombocytopenia
Enrollment 213 participants
Start Date 2023-04-25
Primary Completion 2025-03-03 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-04-16